Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Simvast CR
- Development stage
- Unknown
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Simvast CR is a controlled-release formulation of simvastatin developed by Hanmi Pharmaceutical Company Limited for the treatment of hyperlipidemia and dyslipidemia. As a small molecule HMG-CoA reductase inhibitor, it works by inhibiting the rate-limiting enzyme in the cholesterol biosynthesis pathway in the liver. This action results in a significant reduction of total cholesterol, LDL cholesterol, triglycerides, and apolipoprotein B, while simultaneously increasing HDL cholesterol levels. The controlled-release delivery system was designed as part of Hanmi's incrementally modified drug platform to allow for morning dosing, providing a more flexible alternative to the traditional evening dosing required for immediate-release statins. It has been specifically evaluated in Phase 4 clinical trials for its efficacy and safety in patients with stage 3-5 chronic kidney disease.
- Brand names
- Simvast CRSimvast
- Other names
- controlled-release simvastatinsimvastatin CR
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on Simvast CR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Simvast CR.